D.A.B. v. Brown
Decision Date | 04 November 1997 |
Docket Number | No. C2-97-817,C2-97-817 |
Citation | 570 N.W.2d 168 |
Parties | D.A.B. et al., Appellants, v. David R. BROWN, Caremark, Inc., Genentech, Inc., Respondents. |
Court | Minnesota Court of Appeals |
Syllabus by the Court
A patient's claim against a physician who receives kickbacks for prescribing drugs sounds in medical malpractice.
Richard M. Ihrig, Michael D.L. Olafson, Steven M. Pincus, Lindquist & Vennum, P.L.L.P., Minneapolis, for appellants.
Kay Nord Hunt, Phillip A. Cole, Mary I. King, Lommen, Nelson, Cole & Stageberg, P.A., Minneapolis, for respondent David R. Brown.
John W. Lundquist, Thompson, Lundquist & Sicoli, Ltd., Minneapolis, and Howard M. Pearl, Catherine W. Joyce, Winston & Strawn, Chicago, IL, for respondent Caremark, Inc.
Jeffrey J. Keyes, Jay W. Schlosser, Briggs & Morgan, P.A., Minneapolis, and Charles B. Sklarsky, Robert R. Stauffer, Jenner & Block, Chicago, IL, for respondent Genentech, Inc.
Considered and decided by SHORT, P.J., and CRIPPEN and WILLIS, JJ.
This case arises out of a physician's prescription for Protropin, a synthetic growth hormone drug. A putative class of patients and their parents sued the physician, drug manufacturer, and drug distributor for breach of fiduciary duty, conspiracy to breach that duty, common law fraud, negligent misrepresentation, and violation of the Minnesota Prevention of Consumer Fraud Act, Minn.Stat. §§ 325F.68-.70 (1996). On appeal from a dismissal with prejudice, the putative class argues: (1) physicians should be subject to the law of fiduciaries, and (2) their complaint alleges sufficient injury to support a statutory fraud claim.
Protropin is a drug used in the treatment of growth hormone inadequacy in children. Typically, a doctor prescribes Protropin for a child from childhood through the teenage years. The child self-administers the drug at home, several times a week. Depending on the dosage, Protropin treatment can cost between $20,000 and $30,000 per year.
Genentech, Inc. (manufacturer), developed and manufactured Protropin. In 1985, the Food and Drug Administration approved the drug and permitted the manufacturer seven years of market exclusivity. Caremark, Inc. (distributor), served as the exclusive, non-hospital based pharmacy distributor of Protropin in the United States. From February of 1986 until September of 1994, Dr. David R. Brown (doctor), a Minneapolis physician specializing in pediatric endocrinology, prescribed Protropin to more than 200 patients.
On August 4, 1994, the government indicted the doctor, distributor, and others on multiple counts of mail fraud, wire fraud, money laundering, and violation of the Medicaid/Medicare Anti-Kickback statute, 42 U.S.C. § 1320a-7b(b) (1996). On June 15, 1995, the distributor pleaded guilty to one count of mail fraud and agreed to pay several million dollars in fees, penalties, and restitution. As part of that plea agreement, the distributor stipulated that it made payments to the doctor to induce him to refer patients for Protropin-related services and supplies. A federal jury then convicted the doctor of two counts of violating the federal statute, but the trial court granted a new trial because the doctor was denied his Sixth Amendment right to trial by an impartial jury. See generally United States v. Brown, 913 F.Supp. 1324, 1333 (D.Minn.1996), aff'd, 108 F.3d 863 (8th Cir.1997).
On July 8, 1996, six patients and their parents filed suit against the doctor, distributor, and manufacturer for failing to disclose the kickback scheme. Five of the six patients had terminated treatment with the doctor by May of 1994. On a defense motion, the trial court dismissed the lawsuit with prejudice for failure to state a claim pursuant to Minn. R. Civ. P. 9.02 and 12.02(e). The putative class appeals dismissal of the claims alleging breach of a fiduciary duty, conspiracy to breach that duty, and violation of the state fraud statute. The doctor, distributor, and manufacturer seek review of the trial court's determination that, due to fraudulent concealment, the two-year statute of limitations commenced on August 4, 1994.
I. Does the complaint set forth a legally sufficient claim for breach of fiduciary duty and conspiracy to breach that duty?
II. Does the complaint set forth a legally sufficient claim under the Consumer Fraud Act?
III. Do the patients' parents have standing to sue the doctor, distributor, or manufacturer?
In reviewing a dismissal for failure to state a claim upon which relief can be granted, the only question before us is whether the complaint sets forth a legally sufficient claim for which relief can be granted. Elzie v. Commissioner of Pub. Safety, 298 N.W.2d 29, 32 (Minn.1980); Davis v. State Dep't of Corrections, 500 N.W.2d 134, 135 (Minn.App.1993), review denied (Minn. July 15, 1993). We consider as true the factual allegations made in the complaint, and address solely their legal sufficiency. See Minn. R. Civ. P. 12.03 ( ).
A physician is prohibited by Minn.Stat. § 147.091, subd.1 (p)(1) (1996), from receiving compensation for the referral of patients or the prescription of drugs. That statute protects consumers from economic arrangements in the medical arena that would increase the cost of health care, restrict access to goods and services, or otherwise harm consumer interests. The statute does not provide a private remedy. See Minn. R. 5620.0100 (1995) ( ). Rather, a violation of the statute subjects the physician to disciplinary action by the Board of Medical Examiners. Minn.Stat. § 147.091, subd. 1 (1996). In addition, a physician who knowingly accepts remuneration in return for referrals involving Medicare or Medicaid patients is guilty of a felony under the federal anti-kickback statute, 42 U.S.C. § 1320a-7b(b) (1996).
Apart from these administrative remedies and criminal sanctions, a patient may sue a physician for failure to disclose material facts relating to treatment if the lack of disclosure prevents a patient from making an informed decision about treatment. Cornfeldt v. Tongen, 295 N.W.2d 638, 640 (Minn.1980) (Cornfeldt II ); Cornfeldt v. Tongen, 262 N.W.2d 684, 699 (Minn.1977) (Cornfeldt I ). It is well accepted that patients deserve medical opinions about treatment plans and referrals unsullied by conflicting motives. See Council on Ethical and Judicial Affairs, Am. Med. Ass'n, Current Opinions of the Council on Ethical and Judicial Affairs of the American Medical Association--1986, § 8.06, at 31 (1986) ( ); see also David Burda, AMA Toughens Guidelines on Physician Self-Referrals, 21 Mod. Healthcare 4, 4 (1991). The putative class suggests we put "teeth" into that duty by applying traditional fiduciary concepts. See generally Marc A. Rodwin, Medicine, Money, and Morals: Physicians' Conflicts of Interest, 234-36 (1993) ( application of traditional fiduciary law to doctors engaged in kickback schemes); see, e.g., Brandt v. Medical Defense Assocs., 856 S.W.2d 667, 670 (Mo.1993) ( ). However, in reviewing a case dismissed for failure to state a claim, we look at the essence of the allegations contained in the complaint, and not at the legal concepts advocated by counsel. See Kaiser v. Memorial Blood Ctr., 486 N.W.2d 762, 767 (Minn.1992) ( ).
Although the putative class attempts to frame the issue before us as one involving a breach of fiduciary duty, the gravamen of the complaint sounds in medical malpractice. The distributor stipulated in federal court that it made payments to the doctor to induce him to refer patients for Protropin-related services and supplies. Therefore, the kickback scheme involving the doctor, drug manufacturer, and drug distributor was dependent on the medical diagnosis, treatment, and care of the patients. Cf. Stackhouse v. Emerson, 611 So.2d 1365, 1366 (Fla.Dist.Ct.App.1993) ( ); Tighe v. Ginsberg, 146 A.D.2d 268, 540 N.Y.S.2d 99, 100 (N.Y.App.Div.1989) ( ). The complained-of kickback scheme relates directly to the putative class's Protropin treatment.
Thus, despite counsel's creative characterizations and foreign support, this case is a malpractice action. The doctor's duty to disclose the kickback scheme presents a classic informed consent issue. See Cornfeldt I, 262 N.W.2d at 699 ( ); see also Carol Michna, The Patient Has Not Been Informed: A Proposal For A Physician Conflict of Interest Disclosure Law, 27 Val. U.L.Rev. 495, 528 (1993) ( ). To hold otherwise would permit avoidance of every statute defining the physician/patient relationship. Indeed, it is difficult to imagine any medical malpractice claim that would not be pleaded as a breach of fiduciary duty claim in order to bypass legislative procedures aimed at implementing common law. See, e.g., Minn.Stat. § 144.651 (1996) ( ). We decline to create a new cause of action simply to permit the putative class to avoid showing injury or to circumvent the legislatively mandated statute of...
To continue reading
Request your trial-
Neade v. Portes
...at 809-10, 237 Ill.Dec. 788, 710 N.E.2d 418, citing Hales v. Pittman, 118 Ariz. 305, 309, 576 P.2d 493, 497 (1978); D.A.B. v. Brown, 570 N.W.2d 168 (Minn.App.1997); Garcia v. Coffman, 124 N.M. 12, 19, 946 P.2d 216, 223 (1997); Awai v. Kotin, 872 P.2d 1332, 1337 (Colo.App.1993); Spoor v. Ser......
-
Pavlik v. Kornhaber
...for malpractice. Neade, 193 Ill.2d at 441, 250 Ill.Dec. 733, 739 N.E.2d at 501 (referring to arguments raised in D.A.B. v. Brown, 570 N.W.2d 168 (Minn.App.1997)). We have similar concerns in the instant case. The breach of fiduciary duty count was not included in the original complaint and ......
-
Le v. Wells Fargo Bank, Na, Schiller &, Adam, P.A.
...provide a basis for a conspiracy to commit such act. The claim for civil conspiracy should therefore be dismissed. D.A.B. v. Brown, 570 N.W.2d 168, 172 (Minn. App. 1997) (citing Harding v. Ohio Cas. Ins. Co., 41 N.W.2d 818, 824-25 (Minn. 1950)). Moreover, Plaintiffs have not alleged facts t......
-
Brinkman v. Bank of Am., N.A.
...of liability is without merit. Furthermore, Minnesota does not recognize civil conspiracy as an independent tort, see D.A.B. v. Brown, 570 N.W.2d 168, 172 (Minn.App.1997), and Plaintiffs' fraud claim is not pleaded with particularity, as required by Fed.R.Civ.P. 9. See alsoMinn. R. Civ. P. ......
-
Physician Conflicts of Interest in Court: Beyond the Independent Physician Litigation Heuristic
...375-83 (2003) (characterizing private enforcement of conflicts of interest standards as absent or weak). 3. See, e.g., D.A.B. v. Brown, 570 N.W.2d 168, 171 (Minn. Ct. App. 1997) (holding that "the gravamen of the complaint sounds in medical malpractice . . . [because] the kickback scheme in......
-
Medical Malpractice
...existing between a physician and a patient. A duty that arises out of that relationship is one of loyalty. D.A.B. v. Brown , 570 N.W.2d 168 (Minn. 1997). 4. Admissibility of financial incentives in malpractice cases • Relevant evidence is admissible unless it is prohibited by some statute, ......